Chester County News and Community Website
WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently received a Discipline Review Letter from the U.S. Food and Drug Administration identifying only minor administrative changes for its ketamine application …
NRx Reports FDA Feedback, Progress on Ketamine Application Read More WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) said it supports an executive order signed April 18, 2026, directing federal agencies to accelerate research and regulatory pathways for treatments targeting serious …
NRx Pharmaceuticals Responds to Executive Order on Mental Health Treatments Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently appointed Glenn Tyson as its first chief commercial officer as the company prepares for anticipated regulatory milestones tied to its ketamine-based …
NRx Pharmaceuticals Appoints Glenn Tyson as Chief Commercial Officer Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) recently received preliminary feedback from the U.S. Food and Drug Administration on labeling for its preservative-free ketamine product, as the company continues …
NRx Receives FDA Feedback on Ketamine Drug Labeling Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) said the U.S. Food and Drug Administration has not identified bioequivalence deficiencies in its abbreviated new drug application for a preservative-free ketamine …
NRx Says FDA Finds No Bioequivalence Issues in Ketamine Filing Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) said it has received written confirmation from the U.S. Food and Drug Administration supporting a path toward approval of its depression treatment …
NRx Says FDA Will Review NRX-100 Without New Trials Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced it has appointed Joshua C. Brown, MD, PhD, as chief medical innovation officer to support the company’s development of treatments for …
NRx Pharmaceuticals Appoints Joshua C. Brown Chief Medical Innovation Officer Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) said it received guidance from the U.S. Food and Drug Administration that could allow the company to file a New Drug Application …
NRx Reports FDA Guidance on NRX-100 Approval Path Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) said it will hold its 2025 annual meeting of stockholders on March 23, 2026, at 10:00 a.m. Eastern Time in a virtual-only …
NRx Pharmaceuticals (NASDAQ: NRXP) Sets Virtual Annual Meeting for March Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. said it has secured Fast Track designation from the U.S. Food and Drug Administration for NRX-100, a preservative-free ketamine formulation aimed at treating suicidal …
FDA Fast Track Puts Ketamine-Based Therapy in Spotlight for Suicide Care Read More